The impact of shingles can be serious and long-lasting

Shingles is well known to cause a painful rash, blisters and excruciating nerve pain that can last for months, or even years.1,3

ZOSTAVAX is the only single-dose shingles vaccination funded on the National Immunisation Program (NIP) for eligible adults 70–79 years.6,7*

*NIP catch-up program for people aged 71–79 is time limited.8

ZOSTAVAX is a live vaccine, check contraindications before prescribing.6


For adults aged 70-79 years.8

ZOSTAVAX single-dose shingles vaccination, available on the NIP for eligible patients.6,7

  1. Visit Community Immunity for resources to support shingles vaccination in your practice.
  2. Use your practice software to identify eligible patients.
  3. Recall eligible patients with letters, phone calls and sms reminders.
  4. Recommend vaccination to eligible patients visiting for other reasons, like influenza vaccination.

Remember – Your recommendation is critical to protect your eligible patients from shingles.6,11


 

PBS Information: This product is listed on the National Immunisation Program (NIP). Refer to the NIP Schedule.

Before prescribing, please review Product Information available at http://seqirus.com.au/PI. Further information is available on request from Seqirus.

1. Harpaz R et al. MMRW 2008 Jun 6; 57(RR-5):1–30. 2. National Centre for Immunisation Research and Surveillance. Herpes Zoster Fact Sheet. Available at: http://www.ncirs.edu.au/assets/provider_resources/fact-sheets/herpes-zoster-vaccine-fact-sheet.pdf [Accessed February 2020]. 3. Oxman MN et al. In: Arvin AM et al (EDs). Varicella-Zoster Virus: Virology and Clinical Management 2000: 246–75. 4. Langan SM et al. Clin Infect Dis 2014; 58:1497–1503. 5. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook, Australian Government Department of Health, Canberra, 2018, immunisationhandbook.health.gov.au. [Accessed February 2020]. 6. Zhang Y et al. J Stroke Cerebrovasc Dis. 2017;26(8):1807-1816. 7. Erskine N et al. PLoS One. 2017;12(7):e0181565. 8. Minassian C et al. PLoS Med. 2015;12(12):e1001919. 9. MacIntyre R et al. PLos ONE 2015; 10(4):e0125025. 10. ZOSTAVAX® Approved Product Information. 11. Department of Health. Immunise Australia Program. National Immunisation Program Schedule. Available at: https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule. [Accessed February 2020]. 12. Immunise Australia Program. Older Australians. Available at: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/older-australians [Accessed February 2020]. 13. Menzies R et al. Med J Aust 2017; 206 (6):238–239.


Seqirus (Australia) Pty Ltd. 63 Poplar Road, Parkville, VIC 3052. ABN 66 120 398 067. Medical Information: 1800 42 865. Seqirus™ is a trademark of Seqirus UK Limited or its affiliates. Date of preparation: February 2020. SEQ/PNEU/0518/0116b

Cart

Cart

Item removed. Undo